Biotech Catalyst Insights
Dated research notes on biotech catalysts. Read each note's publication and update dates, and check the original records for current status.
Start with the trial-evidence checklist or the rNPV assumption guide before interpreting a catalyst.
NVG-291 RESTORE Phase 3 Trial: Actual September 28 Start, Recruiting Status and Evidence Gaps
ClinicalTrials.gov now records an actual September 28, 2026 start for NervGen’s NVG-291 RESTORE trial. Recruiting status and planned enrollment do not establish efficacy or completed enrollment.
NERVGEN PHARMA CORP. (NGEN)
Correction: Ramantamig TRIlogy-7 Sponsor and Actual Start Date
ClinicalTrials.gov identifies Janssen Research & Development as the sponsor of TRIlogy-7 and records an actual September 9, 2026 start. The earlier GH Research attribution is withdrawn.
Novo Nordisk Zenagamtide Phase 3 Obesity Trial: Recruiting; Actual Start Registered
ClinicalTrials.gov lists NCT07668414 as recruiting, with 2026-09-22 marked as an actual start. Registry update posted 2026-09-28.
Novo Nordisk A/S (NVO)
AbbVie ABBV-1480 Phase 3 Lung Cancer Trial: Recruiting; Start Date Still Estimated
ClinicalTrials.gov lists NCT07756645 as recruiting, with 2026-09-22 marked as an estimated start. Registry update posted 2026-10-20.
AbbVie Inc. (ABBV)
AstraZeneca Laroprovstat/Rosuvastatin Phase 3 Trial: Recruiting; Actual Start Registered
ClinicalTrials.gov lists NCT07619118 as recruiting, with 2026-09-10 marked as an actual start. Registry update posted 2026-10-05.
ASTRAZENECA PLC (AZN)
Jazz JZP926 Phase 2/3 Epilepsy Trial: Recruiting; Actual Start Registered
ClinicalTrials.gov lists NCT07723963 as recruiting, with 2026-09-18 marked as an actual start. Registry update posted 2026-10-06.
Jazz Pharmaceuticals plc (JAZZ)
Corbus CRB-701 Phase 3 Oropharyngeal Cancer Trial: Recruiting; Actual Start Registered
ClinicalTrials.gov lists NCT07768189 as recruiting, with 2026-09-29 marked as an actual start. Registry update posted 2026-10-08.
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Praxis Relutrigine PDUFA Date Moved to December 27, 2026
Praxis's relutrigine PDUFA date moved from September 27 to December 27, 2026. The June 29 company announcement and SEC filing confirm the FDA review extension.
Praxis Precision Medicines, Inc. (PRAX)
ImmunityBio NAI Sepsis Trial: Updated Phase 2 Plan, Estimated Start and Registry Conflicts
The NAI sepsis registry now lists a 50-participant Phase 2 study and an estimated October 15, 2026 start. Recruitment has not begun according to the record; masking details conflict.
ImmunityBio, Inc. (IBRX)